CytomX Therapeutics

CYTOMX THERAPEUTICS INC

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

The,Gap,Hanging,Sign,On,The,Building,At,The,Headquarters

News

Pre-Market Outlook

Movers

Trading Ideas

AVGO

BBAI

CLAR

CTMX

CUTR

FAMI

GENK

GRRR

LUNR

NDLS

PSTV

RAPP

RIME

SERV

SUNE

Why Gap Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Cancer-Image by PDPics from Pixabay-

Analyst Color

Biotech

Earnings

Equities

Upgrades

Health Care

Price Target

Analyst Ratings

General

Initial data from CytomX Therapeutics&#39; CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.

Analysts&#39; Varied Perspectives On CytomX&#39;s CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer

gold miner shutter2

Eurozone

Commodities

Intraday Update

Markets

CCSI

CPOP

EMKR

RBLX

SEZL

TIVC

Gold Moves Higher; Roblox Issues Weak Outlook

CytomX Therapeutics Inc

Press Releases

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Aligos Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Citius Oncology

Fortress Biotech

Forte Biosciences

Gain Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Immix Biopharma

Immuneering Corporation - Class A Common Stock

Immuneering

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Kronos Bio

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

MAIA Biotechnology

Metagenomi

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OKYO Pharma

OSR Holdings

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PepGen

Serina Therapeutics

Spero Therapeutics

Shattuck Labs

X4 Pharmaceuticals

Piper Sandler

BMO Capital

Wedbush

Jefferies

Mizuho

Comments

CytomX Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga